These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 17009262

  • 1. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.
    Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
    [Abstract] [Full Text] [Related]

  • 2. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 3. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
    Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Rubio A, Guerrero JM, Osuna C.
    J Pineal Res; 2008 Sep 15; 45(2):204-11. PubMed ID: 18507713
    [Abstract] [Full Text] [Related]

  • 4. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M.
    Arthritis Rheum; 2005 Dec 15; 52(12):3987-96. PubMed ID: 16320345
    [Abstract] [Full Text] [Related]

  • 5. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 15; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 15; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 7. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.
    Zeller GC, Hirahashi J, Schwarting A, Sharpe AH, Kelley VR.
    J Am Soc Nephrol; 2006 Jan 15; 17(1):122-30. PubMed ID: 16291836
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine, an inhibitor of polyamine synthesis: II. Beneficial effects on the development of a lupus-like disease in MRL-lpr/lpr mice.
    Claverie N, Pasquali JL, Mamont PS, Danzin C, Weil-Bousson M, Siat M.
    Clin Exp Immunol; 1988 May 15; 72(2):293-8. PubMed ID: 3409547
    [Abstract] [Full Text] [Related]

  • 9. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
    Zhai ZF, Zhou CL, Zhong BY, Ao JH, Hao F.
    Zhonghua Yi Xue Za Zhi; 2008 Feb 05; 88(6):406-10. PubMed ID: 18581896
    [Abstract] [Full Text] [Related]

  • 10. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
    Apelgren LD, Bailey DL, Fouts RL, Short L, Bryan N, Evans GF, Sandusky GE, Zuckerman SH, Glasebrook A, Bumol TF.
    Cell Immunol; 1996 Oct 10; 173(1):55-63. PubMed ID: 8871601
    [Abstract] [Full Text] [Related]

  • 11. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T, Yoshimoto T, Tsubura A, Matsuzawa A.
    Cell Immunol; 2001 Jun 15; 210(2):77-86. PubMed ID: 11520074
    [Abstract] [Full Text] [Related]

  • 12. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.
    Nicoletti F, Di Marco R, Zaccone P, Xiang M, Magro G, Grasso S, Morrone S, Santoni A, Shoenfeld Y, Garotta G, Meroni P.
    Eur J Immunol; 2000 Feb 15; 30(2):438-47. PubMed ID: 10671199
    [Abstract] [Full Text] [Related]

  • 13. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice.
    Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR.
    J Am Soc Nephrol; 2005 Nov 15; 16(11):3264-72. PubMed ID: 16221871
    [Abstract] [Full Text] [Related]

  • 14. Lupus nephritis reoccurs following transplantation in the lupus prone mouse.
    Hamar P, Wang M, Godo M, Kokeny G, Rosivall L, Ouyang N, Heemann U.
    Lupus; 2010 Feb 15; 19(2):175-81. PubMed ID: 19946036
    [Abstract] [Full Text] [Related]

  • 15. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M.
    Clin Immunol; 2010 Aug 15; 136(2):188-96. PubMed ID: 20403731
    [Abstract] [Full Text] [Related]

  • 16. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 17. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 01; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 18. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
    Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.
    Arthritis Rheum; 2002 Nov 01; 46(11):3083-95. PubMed ID: 12428253
    [Abstract] [Full Text] [Related]

  • 19. Knocking out of CD38 accelerates development of a lupus-like disease in lpr mice.
    Viegas MS, Silva T, Monteiro MM, do Carmo A, Martins TC.
    Rheumatology (Oxford); 2011 Sep 01; 50(9):1569-77. PubMed ID: 21586522
    [Abstract] [Full Text] [Related]

  • 20. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
    Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH.
    Arthritis Rheum; 2001 Jun 01; 44(6):1320-30. PubMed ID: 11407691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.